WO2004067733A1 - Ameliorations apportees dans et a propos de la croissance cellulaire - Google Patents

Ameliorations apportees dans et a propos de la croissance cellulaire Download PDF

Info

Publication number
WO2004067733A1
WO2004067733A1 PCT/GB2004/000397 GB2004000397W WO2004067733A1 WO 2004067733 A1 WO2004067733 A1 WO 2004067733A1 GB 2004000397 W GB2004000397 W GB 2004000397W WO 2004067733 A1 WO2004067733 A1 WO 2004067733A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell growth
fibre
scaffolding
support means
cell
Prior art date
Application number
PCT/GB2004/000397
Other languages
English (en)
Inventor
Ian Philip Middleton
Christopher Louis Ives
Original Assignee
Himedica Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Himedica Limited filed Critical Himedica Limited
Publication of WO2004067733A1 publication Critical patent/WO2004067733A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/14—Scaffolds; Matrices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/56—Fibrin; Thrombin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Definitions

  • This invention relates to cell growth scaffolding and methods of manufacturing cell growth scaffolding.
  • the invention further relates to methods of growing cells, particularly to methods of growing cells outside (in vitro and ex vivo) and inside (in vivo) the body of an organism.
  • Cell growth media are known to enable growth and maintenance of mammalian, and other cells in vi tro, and to encourage differentiation of cells to, and maintenance of, a defined phenotype .
  • the liquid medium is the cell culture medium, which also contains the specific membrane receptor binding molecules, growth factors, cytokines, nutrients etc, and much of the initial development work in cell culture was focused on this aspect of cell growth.
  • the substrates on which cells are currently grown in known cell growth media generally comprise glass surfaces, polystyrene surfaces and the like.
  • Such cell growth surfaces suffer problems in that they generally consist of only a single functionality on the surface, with which to adhere cells, they are non-specific, and the surfaces are smooth and flat, non-porous and two dimensional.
  • a cell growth surface such as polystyrene is contacted with one or more cells, to adhere the cells to the surface, and the surface bathed in cell culture liquid. Cells grown in this manner can generally only grow to a thickness of approximately 2-3mm before becoming non-viable.
  • US patent 5,266,476 highlights the limitations of polystyrene surfaces for cell growth as an example of current two dimensional cell culture substrates.
  • the proposed solution in US 5,266,476 is the construction of a polyester fibre matrix comprising various coatings on the fibre to enhance attachment of cells to the fibre. As a fibre, it has some three dimensional profile, but cell growth from the fibres would again be generally limited in thickness .
  • the third key factor in viability of cell cultures is fluid mechanical forces. Until very recently no allowance has been made for fluid mechanical forces in a life of the cell in cell culture. Most culture is typically carried out in an essentially stationary environment where there may be intermittent exposure to high levels of fluid shear, at time of changing the growth liquid bathing the cells for example. Where perfusion is used it is used as a means of refreshment of culture media to remove waste and supplement nutrients, and cells are considered to be at risk of shear damage if exposed directly to flow so this is generally avoided. In most cases, the cell culture environment contains a non-compliant substrate which will only transmit shear stress component and not shear strain. It has become clear in recent years that cells will alter shape, up regulate and down regulate secretary activity etc and generally modify gene expression in relation to fluid mechanical forces. No culture systems today offer perfusion as a means of cell stimulation for routine culture.
  • Such drivers include growth factors, cell contacts, surface functionality, surface geometry/profile, surface energy, surface porosity/permeability, surface compliance/deformability, shear stress, shear strain and/or oxygen partial pressure. It would be advantageous to provide a cell culture medium which would allow cell growth to provide tissues of much larger thickness than can be achieved in current cell culture media. It would further be advantageous to provide a cell growth media in which a pluripotent stem cell, and undifferentiated cells, could be adhered to the media and be driven down a specific differentiation pathway or conversely a differentiated cell could be adhered to the media and maintain both viability and original phenotype.
  • a cell growth median which is three dimensional in nature, and enables cell growth within the three dimensional structure. It would furthermore be advantageous to provide a three dimensional cell growth structure throughout which cell growth factors and nutrients can perfuse in a all-encompassing or optionally selective manner, in order to enable continual viability and maintenance of phenotype of cells and tissues growing within the three dimensional matrix.
  • a cell growth scaffolding arranged, in use, to mount one or more cells, comprising at least one fibre, wherein at least a portion of the fibre is mounted in a fluid perfusable support means.
  • the fibre may be a hollow fibre.
  • the hollow fibre may comprise one or more apertures in the fibre wall.
  • one or more cells may be mounted inside the hollow fibre and/or on the outside of the hollow fibre.
  • the fibre may be a substantially solid fibre.
  • one or more cells may be mounted on the outside of the fibre.
  • the fibre may be a porous fibre, in which one or more cells may be mounted in one or more pores and/or on the surface of the fibre. Preferably there are a plurality of fibres.
  • the fibres may be separate fibres, and may be oriented in any spatial orientation with respect to each other, such as parallel, transverse, perpendicular or any combination thereof.
  • the cell growth scaffolding comprises a plurality of fibres oriented spaced apart and parallel with each other.
  • the cell growth media comprises a plurality of fibres, a first portion of which are oriented spaced apart and parallel with each other, and a second portion of which are oriented transverse to the first portion, and preferably spaced apart and parallel with each other.
  • At least some of the fibres are preferably connected.
  • at least some of the fibres are connected to form a three dimensional network of interconnected fibres.
  • the three dimensional network may comprise a scaffold structure or framework of connected fibres.
  • the fibres may be connected by knitting, weaving, embroidery or the like, for example, or by non-weaving techniques, such as needling of fibres to form a non-woven felt, or electrodeposition of fibres to form a matted or flocked surface network, for example or by any combination of these techniques .
  • the density of fibres within the three dimensional network will vary according to the application, cell type and cell numbers to be cultured, as will the distance between cells. It is envisaged that in certain embodiments fibre density per unit cubed, and/or the distances between fibres, will be equal throughout the cell growth scaffolding. In alternative embodiments it is envisaged that within the growth scaffolding different regions will contain different numbers of fibres or portions of fibres such that fibre density and spatial distance between fibres will vary for each or some of the regions.
  • Suitable materials for use as fibres in the cell growth media of the invention may comprise any material to which cells are capable of anchoring to and which do not substantially damage anchored cells.
  • Suitable materials include synthetic material.
  • Suitable synthetic materials include polyethylene terephthalates, polyesters, polyamides, polyolefins and copolymers thereof, polyvinyl chloride and copolymers thereof (for example vinyl chloride with acrylonitrile, vinyl acetate, polyvinylidene halide, polyether sulphone or vinylidene chloride) polyacrylics, polyacrylates, super absorbent fibres based on acrylic acid or itaconic acid, polyurethanes , polyimides, polylactides, polyglycollides and co-polymers> mixtures and salts of any of the aforesaid polymers.
  • the fibres used in the cell growth scaffolding of the invention comprise, at least in part, a biopolymer, such as a saccharide biopolymer, a protein or a polypeptide (whether natural or synthetic) , for example.
  • a biopolymer such as a saccharide biopolymer, a protein or a polypeptide (whether natural or synthetic) , for example.
  • saccharide polymers or oligomers Particularly useful as a fibre material are saccharide polymers or oligomers.
  • suitable polysaccharides include polymers and co-polymers of : alginic acid and salts thereof; polymers of cellulose and salts thereof; polymers of carboxymethylcellulose and salts thereof; polymers of carrageenan and salts thereof; polymers of hyaluronic acid and salts thereof; polymers of heparin and salts thereof.
  • the fibres may comprise more than one material, and may for example comprise a composite fibre of two or more materials.
  • a composite fibre may comprise both a biopolymer component and a synthetic plastics component.
  • the composite fibre may be fabricated by any suitable technique such as by knitting, weaving or embroidering different materials into the composite fibre, for example.
  • the composite fibre may comprise a plurality of thinner fibres of two or more different materials, combined to form the thicker composite fibre.
  • the exact makeup of the fibres will depend on which type of cell or cells are intended to be grown on the cell growth scaffolding. Thus the choice of fibre will depend on one or more of the following characteristics: nonspecific cell adhesion; specific cell adhesion; strength; durability; biodegradation; ability to provide nutrients for growing cells; porosity; fluid permeability; growth factor and ligand binding ability.
  • a network of chitin, chitosin and/or hyaluronate fibres provides good non-specific cell adhesion through ionic groups (both positively and negatively charged) on the fibre surface, and further provides good strength, durability and flexibility.
  • the or each fibre may comprise surface groups able to react with or bind specific cell types or specific surface groups on cells.
  • the or each fibre may comprise cell adhesion molecules bound or connected to the surface of the fibre, arranged in use to adhere to a specific cell type or types.
  • Suitable proteins for use as cell adhesion molecules include integrin, fibrin, fibrinogen and laminin, for example.
  • cell adhesion agents include peptides or protein molecules, which may specifically react or bind to a ubiquitous or specific protein on a cell surface, such as a receptor, membrane protein, ion channel, enzyme or the like, for example.
  • At least one fibre is constructed entirely from one or more biopolymers .
  • the or each biopolymer is independently produced by a fibre spinning technique, which may be for example, wet spinning, centrif ngal spinning, or electrostatic spinning.
  • One or more fibres may comprise one or more cell growth factors, cytokines, cell nutrients, proteins, peptides or other cell growth promotion agents, mounted within and/or on the fibre.
  • the fibres may be fabricated by spinning the fibre material in the presence of one or more growth factors, cytokines, cell nutrients, proteins, peptide or other cell growth promotion agents, for example, such that the resultant fibre comprises the agent or agents entrapped, entrained or bonded to the fibre.
  • the cell growth scaffolding comprises at least one load bearing fibre and at least one fibre arranged in use to mount one or more cells.
  • the load bearing fibre is preferably a synthetic plastics fibre, such as polyester, for example.
  • the load bearing fibre does not comprise any growth factors, cytokines, cell nutrients, peptide, proteins or cell growth promotion agents mounted within and/or on the load bearing fibre.
  • substantially the whole of the or each fibre is mounted within the fluid perfusable support means .
  • the support means surrounds substantially the entire network and substantially fills the spaces between each fibre in the network.
  • the support means is such that one or more cells can grow, proliferate and/or differentiate within the support means.
  • the fluid perfusable support means is preferably a solid or gel (including hydrogel) , but in certain embodiments may be a viscous liquid.
  • viscous liquid we mean a liquid having a centipoise value of at least 8,000 centipoise (cP) at ambient temperature, preferably at least 9,000 cP and more preferably at least 10,000 cP.
  • the viscous liquid is preferably such that the or each fibre mounted in the liquid is substantially immovably supported, when the cell growth media is still.
  • the support means may comprise one or more channels, conduits and/or cavities formed in the support means and which may extend partially or entirely therethrough.
  • the support means comprises a connection means, arranged in use to operably cooperate with a connection means, of a second cell growth scaffolding of the invention.
  • the support means may comprise at least one ridge on a surface and/or at least one channel on a surface, which in use form the connection means, operably cooperable with a corresponding channel and/or ridge on another support means .
  • the fluid perfusable support means is most preferably a gel, especially a hydrogel, and may be in the dehydrated state and thus be a solid, or in the hydrated state.
  • the hydrogel comprises polymerised hydrophilic monomers, and may comprise a homopolymer, heteropolymer, co-polymer, or a combination thereof.
  • the gel, hydrogel, or solid may comprise a synthetic polymer or a natural polymer.
  • Suitable natural polymers include alginates, agaroses, agars, gelatines, starches, pectins, polysaccharide hydrogels, celluloses, chitosans, collagen, proteins, polypetides, and the like, for example.
  • Synthetic polymers suitable as hydrogels include but are not limited to, polymerised monomers of acrylamides, acrylates, pyrrolidones, acrylic acids, and derivatives and mixtures thereof; for example.
  • Suitable acrylamide monomers include, acrylamide per se, methacrylamide, diacetone acrylamide, N-hydroxy propylmethacrylamide, N,N, -dimethyacrylamide, N- (trishydroxymethyl) acrylamide, N- (trishydroxymethyl) methacrylamide, acryla idopropylsulphonic acid, and salts thereof, 3-acrylamidopropyl ammonium halides, 3- methacrylamidopropopyl ammonium halides, and any mixture thereof, for example.
  • Suitable pyrrolidones monomers include N-vinylpyrrolidone, for example .
  • Suitable acrylates monomers include, for example, 2- hydroxyethylacrylate, 2-hydroxethylmethacrylate, 2- hydroxypropylacrylate, 3 -hydroxpropylmethacrylate , polyethylene glycol monomethyacrylate monomers, preferably having molecular weights of the polyethylene glycol chain from 200 to 10,000, and derivatives and mixtures thereof.
  • Suitable acrylic acid monomers include, for example, acrylic acid, methacrylic acid, acrylic acid- (3- sulphopropyl ester) and derivates and mixtures thereof .
  • hydrogels are copolymers comprising an acrylamide and one or more further polymers preferably selected from an acrylate, a pyrrolidone and an acrylic acid, or derivates thereof.
  • the copolymer comprises up to 40 molar% acrylamide.
  • the hydrogel may be prepared by polymerising the monomers in the presence of a cross-linking agent and/or a free radical initiator.
  • a cross-linking agent is a di-ethylenicaly substituted cross-linking agent.
  • suitable di-ethylenicaly substituted cross-linking agents include di-ethylenicaly substituted dimethacrylates, acrylates, pentaerythritol tetraacrylate, methylene bis-acrylamide, ethylene bis acrylamide and dihydroxyethylenebisacrylamide .
  • the cross-linking agent is added to the monomer composition at a concentration of at least 0.05% by weight of the monomer composition, preferably at least 0.1%, and preferably no more than 20% by weight, more preferably no more than 10%.
  • the free radical initiator is added to the monomer composition to a concentration of at least 0.01% by weight of the monomer composition, preferably at least 0.05%, more preferably at least 0.01%, and suitably no more than 10% by weight of the monomer composition, preferably no more than 5%, and more preferably no more than 1%.
  • Polymerisation of the monomer composition is preferably carried out after substantially removing oxygen from the composition such as by passing a gas such as helium or nitrogen through the composition, or by ultra-sonification or freeze-drying for example.
  • the monomer composition comprises a cross-linking agent polymerisation may be effected by heating at an elevated temperature, preferably between 50°C and 65°C. Heating may be effected for a desired period of time, preferably at least 1 hour, more preferably at least 6 hours, still more preferably at least 12 hours. Heating is preferably effected for no more than 72 hours, more preferably no more than 60 hours and still more preferably no more than 48 hours.
  • the resultant polymer may be subjected to post curing at an elevated temperature, preferably between 60°C and 80°C for a desired period of time, preferably between 1 hour and 5 hours, more preferably around 3 hours .
  • polymerisation of the monomers may be effected by irradiation with long wavelength ultraviolet radiation, for example. If polymerisation is effected by irradiation with ultraviolet radiation preferably a free radical initiator is added to the monomers before or during irradiation.
  • Suitable free-radical initiators include benzoyl peroxide, cumene hydroperoxide, dicumylperoxide, azobis (isobutyronitrate) , azobis (2- methylpropionamide) dihydrochloride, diisopropylazodo carboxylate, N-chloro succinimide, N-bromosuccinimide, ammonium persulphate, potassium persulphate and any combination thereof, for example.
  • the support means may comprise one or more cell growth factors, cytokines, cell nutrients, peptides, proteins or other cell growth promotion agents, mounted within and/or on the support means.
  • the support means comprises a hydrogel formed by polymerising monomers, suitably polymerisation takes place in the presence of the or each cell growth factor, cytokine, cell nutrient, peptide, protein or cell growth promotion agent, in order that said agent is contained within and/or on the resultant polymer.
  • monomers may be bulk polymerised in the dehydrated state, (to form a xerogel) and the resultant bulk dehydrated hydrogel polymer may be machined into the desired size and shape.
  • the dehydrated hydroge.1 polymer may then be contacted with a hydrating solution to form the hydrated hydrogel.
  • the hydrogel monomers may be dispersed, dissolved or mixed with a hydrating solution and polymerised therein to form the hydrated hydrogel .
  • the hydrating solution may be water or a simple salt solution.
  • the hydrating solution is a cell growth medium, preferably comprising one or more cell growth factors, cytokines, nutrients, proteins and/or inorganic salts, for example.
  • Cell growth media suitable as hydrating solutions include Dulbecco's Modified Eagle Medium (DMEM) , Ham's Growth Medium, Ames 1 medium, BGJb medium, Basal medium Eagle, CMRL-1066, Dulbecco's modified Eagle's medium, Fischer's medium, Glasgow minimum essential medium, Ham's F-12 Coon's modification, Iscove's modified Dulbecco's medium, L-15 medium eibovitz, McCoy's 5A medium, Medium 199, Minimum essential medium eagle, nutrient mixture F-10 Ham, RPMI-1640 medium, Swimm's s-77 medium, Way outh MB 752/1 medium and Williams' medium E.
  • DMEM Dulbecco's Modified Eagle Medium
  • Ames 1 medium BGJb medium
  • Basal medium Eagle CMRL-1066
  • Dulbecco's modified Eagle's medium Fischer's medium
  • Glasgow minimum essential medium Ham's F-12 Coon's modification
  • Monomers particularly suited for polymerisation within a hydrating solution include acrylamide-based monomers, which are generally readily soluble in most aqueous-based cell growth media solutions.
  • the monomer solution comprises monomers in at least 1% by weight of the total weight of the solution, preferably at least 2% by weight, more preferably at least 5% by weight and most preferably at least 10% by weight.
  • the monomer solution comprises monomers in an amount of no more than 50% by weight of the total weight of the solution, preferably no more than 40% by weight, more preferably no more than 30% by weight and. most preferably no more than 20% by weight.
  • the monomer solution comprises a cross-linking agent, preferably a di-ethylenically substituted cross- linking agent, in an amount of at least 0.05% by weight of the total weight of the solution, preferably at least 0.1% by weight and more preferably at least 0.5% by weight.
  • the monomer solution comprises the cross-linking agent in an amount of no more than 20% by weight, preferably no more than 10% by weight and more preferably no more than 5% by weight of the total weight of the solution.
  • the monomer solution may comprise a free radical initiator, which is preferably substantially water-soluble.
  • the initiator is present in an amount of at least 0.01% by weight, preferably at least 0.05% by weight, and more preferably at least 0.1% by weight of the total weight of the solution.
  • the initiator is present in an amount of no more than 10% by weight, preferably no more than 5% by weight and more preferably no more than 1% by weight of the total weight of the monomer solution.
  • the monomers are dissolved in a hydrating solution which further comprises a cross- linking agent and/or free radial initiator, and then the monomers polymerised by any suitable means such as curing or ultraviolet irradiation for example.
  • the monomers or monomer solution is placed in a mould of desired dimensions and polymerised therein, to effect a desired shape of the resultant polymer.
  • the mould may include one or more protrusions around which the monomer solution is located.
  • the or each protrusion may comprise a member of uniform cross-section, such as a cylinder, pyramid, parallelepiped and the like for example, such as to create cavities within the polymerised hydrogel.
  • the cavities may take the form of channels, conduits and the like for example.
  • the protrusions may be members of irregular cross-section such that the resultant cavities within the polymerised hydrogel take the form of, for example, cavities spaced apart by conduits or channels.
  • the hydrogel may comprise channels, conduits and/or cavities extending therethrough, formed into the hydrogel after polymerisation, by for example, insertion of a suitably shaped member or drill into the hydrogel .
  • the mould may be shaped to effect incorporation of at least one connection means. Such as a ridge and/or channel, for example, in a surface of the hydrogel.
  • connection means may be formed into the surface after polymerisation of the monomer by stamping, boring, drilling or the like, for example.
  • the or each fibre may be mounted in the hydrogel before, during or after polymerisation of the monomers.
  • the or each fibre is located in the monomers or monomer solution before polymerisation, in the desired orientation, and the monomers or solution subsequently polymerised around the or each fibre.
  • the network is preferably constructed then placed in a monomer solution and the hydrogel polymerised around the fibre network.
  • the or each fibre may be rigidly or fixedly mounted within the support means.
  • the or each fibre may be mounted within the or each channel, conduit and/or cavity.
  • the fluid perfusable support means may comprise one or more water-soluble polymers, as an alternative to, or additional to a hydrogel.
  • One or more water-soluble polymers may be cross-linked by ionic bonds and/or by inter-polymer complexation.
  • Solutions of water soluble polymers and co-polymers containing acidic groups (or their monovalent salts) may be mixed with divalent or trivalent cations, or mixtures thereof, to form an ionically cross-linked gel or alternatively mixed with water soluble polymers or copolymers bearing positively charged groups to yield an inter-polymer complex.
  • water soluble polymers and co-polymers containing acidic groups that may be used are polyacrylic acid, polymethacrylic acid, alginic acid, carrageenan, hyaluronic acid, heparin, chondroitin sulphate, polystyrene sulphonicid-co- alic acid co-polymers, polyacrylic acid - (3-sulphopropy1 ester), polymethacrylic acid - (3-sulphopropy1 ester) and polyacrylamido propyl sulphonic acid.
  • Typical examples of divalent and trivalent ions that may be used to produce ionic crosslinks are Ca 2+ , Ba 2+ , Cu 2+ , Zn 2+ , Sr 2+ and Al 3+ .
  • Examples of water soluble polymers or co-polymers bearing positively charged groups to yield an inter-polymer complex are chitosan, polyethyleneimine, polydimethylaminoethyl acrylate, polydimethylaminoethyl methacrylate, poly (3- acrylamido propyl ammonium chloride) and poly (3- methacryla ido propyl ammonium chloride) . Additionally some pairs of water soluble polymers are known to form gel complexes when mixed via strong inter-chain hydrogen bonds.
  • the fluid perfusable support means may comprise a combination of one or more hydrogels and one more ionically cross-linked water-soluble polymers or polymer complexes, to yield an interconnected polymer network.
  • the fluid perfusable support means may itself be used to set or stabilise the spatial organisation of the or each fibre mounted in the support means, which may be achieved by selective hardening of the support means', in the case of gels and viscous liquids, or through rigidly mounting the or each fibre in a solid or gel support means.
  • cell growth factors, cytokines, cell nutrients, proteins and the like are present on a fibre, or within or on the fluid perfusable support means, they may be present in a defined or selective concentration gradient within the cell growth scaffolding, such as to drive cell growth migration towards or away from defined or desired areas of the scaffolding.
  • the or each fibre, and/or the fluid perfusable support means may comprise different compliance characteristics at different portions thereof, so as to encourage, in use, cell growth or drive cell differentiation at different rates in different regions of the cell growth scaffolding.
  • the cell growth scaffolding, or part thereof may be degradable, preferably biodegradable.
  • the rate of degradation or biodegradation of the cell growth scaffolding, or part thereof may be tailored by selection of particular fibres and/or fluid perfusable support means having desired degradation characteristics.
  • Degradation in vitro may be due to oxidation, reduction or degradation by growing cells, for example.
  • Degradation in vivo or ex vivo may be as above, or by the organism's immune system, for example.
  • the materials used for the fibres and support means of the cell growth scaffolding may be different for in vitro and in vivo/ex vivo use, for the same type of growing cells, due to the need to consider immunogenicity and antigenicity of the cell growth scaffolding in vivo and ex vivo.
  • the or each fibre, and/or the fluid perfusable support means comprise (s) substantially all of the cell growth factors, nutrients, cytokines, proteins, peptides, and the like, mounted in or on the fibre (s) and/or support means, and which are needed for efficient cell growth and viability, and thus any external cell growth media added to the scaffolding may need only be a saline or salt solution and incorporate no, or little, cell growth material.
  • the cell growth scaffolding includes one or more cell growth materials such as growth factors, nutrients, cytokines etc, then preferably the cell growth scaffolding effects both a support and nutrient delivery system, stabilising the or each growing cell and enabling direct presentation of any growth material to the or each cell's luminal or abluminal surface.
  • concentration gradients may be set-up within the cell growth scaffolding to enable selective cell growth and differentiation.
  • a method of growing cells comprising the steps of:
  • the or each cell may be seeded at any point after step (a) in the method but is preferably performed between steps ( a ) and ( b) .
  • cells may be seeded after steps (b) and/or (c) .
  • the or each fibre and the fluid perfusable support means are preferably as described for the first aspect of the invention.
  • the or each cell growth factor a ⁇ d/or nutrient are preferably as described for the first aspect of the invention.
  • the cell growth scaffolding is preferably as described for the first aspect of the invention.
  • a method of manufacturing a cell growth scaffolding of the first aspect of the invention comprising mounting at least one fibre in a fluid perfusable support means or precursor thereof.
  • the fluid perfusable support means or precursor may be monomers or a monomer solution as hereinabove described.
  • the method may comprise mounting the cell growth scaffolding in a support frame or support apparatus.
  • the support frame or apparatus may comprise one or more cell growth solution conduits, cell growth waste conduits, oxygenation units, detoxification units, fluid pumps, and/or thermostats.
  • a method of growing cells in vivo or ex vivo comprising the steps of: (a) mounting at least one fibre in a fluid perfusable support means; and
  • fibres, support means and cell growth scaffolding are as described for the first aspect of the invention.
  • the cell growth scaffolding of the invention may be implanted into a tissue and/or organism enabling cell migration from the tissue or organism into the scaffolding for subsequent growth.
  • One or more cells may be seeded onto at least one fibre before insertion into the support means. Alternatively or additionally one or more cells may be seeded into the support means. Thus cells may be introduced to the cell growth scaffolding before insertion into the tissue and/or organism for subsequent growth and/or migration into the tissue or organism. This can be useful in the repair of damaged tissues.
  • a support means containing one or more fibres allows for enhanced three-dimensional growth of cells in the cell growth scaffolding of the invention.
  • the combination of a fluid perfusable support means and one or more anchoring fibres increases the compliance of the cell growth scaffolding to enhance the phenotypic drivers of the cell growth and expression such as cell contact, cell growth media surface functionalities, and geometries, surface energy, surface porosity/permeability, surface compliance/deformability, shear stress, shear strain and available oxygen to growth cells; as compared to known cell growth media.
  • the cell growth scaffolding of present invention is not only suitable for in vitro growth and culture of cells, but may also be used for in vivo and ex vivo growth and culture of cells.
  • the cell growth scaffolding of the present invention is suitable for implantation in existing tissues or organisms for in vivo and ex vivo culture of cells and tissues.
  • the cell growth scaffolding of the invention is also useful for handling and culturing stem cells, which can be difficult or impossible to culture effectively in known growth media.
  • a cell growth media comprising a fluid perfusable solid cell support means, wherein the support means comprises at least one cell growth agent fixedly mounted in or on the support means .
  • the fluid perfusable solid cell support means comprises a solid support means as described hereinabove for the cell growth scaffolding of the first aspect of the invention, and is more preferably a gel (including hydrogel) .
  • the or each cell growth agent is selected from a growth factor, a cytokine, a cell nutrient, a protein, a peptide, and the like, for example.
  • the fluid perfusable solid cell support means may have one or more cells mounted in or on the support means.
  • the support means may be mounted in a support frame or support apparatus.
  • the support frame and support apparatus may be as described for the third aspect of the invention.
  • the cell growth media of the fifth aspect of the invention may be used in vivo, ex vivo or in vitro, as described for the third aspect of the invention.
  • Figure 1 illustrates a part plan view, part perspective view of a cell growth scaffolding of the present invention
  • Figure 2 illustrates a side elevation of the cell growth scaffolding of Figure 1;
  • Figure 3A illustrates a portion of a fibre of the cell growth scaffolding of Figures 1 and 2;
  • Figure 3B illustrates a portion of a fibre of the cell growth scaffolding of Figures 1 and 2
  • Figure 3C illustrates a portion of a second fibre type of the cell growth scaffolding shown in Figures 1 and 2;
  • Figure 4 illustrates an asymmetric view of a portion of the cell growth scaffolding of Figures 1 and 2 in more detail
  • Figure 5 illustrates an asymmetric view of a portion of the a second embodiment of the cell growth scaffolding of the invention
  • Figure 6 illustrates a cell growth apparatus of the invention
  • Figure 7 illustrates a second embodiment of the cell growth apparatus of the invention in block diagram format.
  • a preferred embodiment of a cell growth scaffolding 2 of the invention comprises a three dimensional network of fibres 6 mounted and encapsulated in a fluid perfusable support means in the form of a hydrogel disc 4.
  • the hydrogel disc 4 includes, running therethrough, a perfusion channel 12, which extends entirely through the hydrogel disc 4. Radiating from the perfusion channel 12 on the upper surface of the hydrogel disc 4, are a plurality of connection means in the form of connection ridges 8, machined into the upper surface of the hydrogel disc 4. The ridges 8 extend from the perfusion channel 12 to the peripheral edge of the hydrogel disc 4.
  • a number of cell growth scaffolding 2 may be stacked on top of each other, with the ridges 8 cooperating with the channels 10 of adjacent discs 4.
  • the cell growth scaffolding 2 was constructed as follows. A mould (not shown) was fabricated in the shape of the hydrogel disc 4, which also included protrusions corresponding with the ridges 8 and channels 10 of the disc 4.
  • the three dimensional fibre network 6 was constructed by wet spinning polyalginate fibres, and knitting or weaving the fibres into the desired three dimensional network. The three dimensional fibre network 6 was then placed in the mould. A monomer solution of acrylamide was prepared, and ethylenically substituted pentaerythritol tetraacrylate cross linking agent added to the liquid acrylamide monomer composition. The liquid monomer composition was then added to a cell growth media solution, Dubbs Modified Eagle solution.
  • the resultant solution was poured into the mould, such that it filled the mould around the fibre network 6.
  • the monomer solution was then polymerised by curing (60°C for 24 hours) and the resultant hydrogel disc 4 containing the three dimensional fibre network 6 removed from the mould.
  • the perfusion channel 12 was then drilled through the centre of the hydrogel disc 4 using a suitable machine tool .
  • desired cells may be seeded into the cell growth scaffolding 2 in a variety of ways. Cells may be adhered to the three dimensional fibre network 6 before placing the network 6 in the mould, and therefore the cells will be seeded on the network 6 when the monomer solution is polymerised to form the hydrogel disc 4. In this situation, differing polymerisation strategies may need to be incorporated in order not to damage or kill off the cells due to excessive heat or ultraviolet radiation on polymerising the monomer solution.
  • the fluid perfusable support means may be a preformed gel, a solid or a viscous liquid and the or each fibre may have one or more cells seeded to the fibre (s) before directly inserting the fibre (s) into the support means.
  • An alternative method of introducing cells into the hydrogel disc 4 is to insert a fibre such as a porous fibre 14 or hollow fibre 20 shown in Figures 3A and 3C, into the perfusion channel 12 and/or through the hydrogel itself in a desired position.
  • the fibre 14 shown in Figure 3A is a solid but porous fibre of any suitable polymer, especially a biopolymer such as chitosan, alginate etc.
  • Cells 16 are adhered to the fibre 14 and within the pores of the fibre 14 until they become fully adhered and flattened as shown in cells 18 of Figure 3A. As shown in Figure 3B, eventually a plurality of cells will be adhered to the solid fibre 14.
  • the fibre 14 may then be inserted into the perfusion channel 12 of the hydrogel disc 4, and suitable growth factor solution containing nutrients and growth factors drawn through the channel 12 as and when desired.
  • suitable growth factor solution containing nutrients and growth factors drawn through the channel 12 as and when desired.
  • the fibre 14 may be inserted through the soft hydrogel disc 4 in any desired position to extend therethrough.
  • a hollow fibre 20 may be incorporated into the hydrogel disc 4.
  • the hollow fibre 20 enable cells to be adhered on the outside of the surface as shown in cells 18 of Figure 3C, and also on the inside of the hollow fibre 20, as shown in cells 22 of Figure 3C.
  • the hollow fibre 20 may be inserted into the perfusion channel 12 such that a bore still remains through the centre of the perfusion channel 12.
  • the hollow fibre 20 may be inserted into the hydrogel disc 4 itself as described above.
  • Figure 4 illustrates a close up perspective view of a portion of the hydrogel disc 4 of a second preferred embodiment of the cell growth scaffolding 2 of the invention, in which a hollow channel 24 has been cast through part of the hydrogel disc 4, and a cell- containing porous fibre 26 has been inserted into the hollow channel 24.
  • the hollow channel 24 extends through the hydrogel disc 4
  • the cell containing fibre 26 extends entirely through the hollow channel 24.
  • the hydrogel disc 4 is bathed in cell growth solution such as Dubbs Modified Eagle solution, and kept at optimum conditions for cell growth. As time passes, cells on the fibre 26 will begin to multiply and form cell growth which can pass through the pores or apertures of the porous hollow channel 24 and into the hydrogel disc 4.
  • the cell growth becomes cell growth capillaries 28, which extend through the hydrogel disc 4, and adhere to fibres in the three dimensional fibre network 6 within the hydrogel disc 4, as shown in Figure 4. Further growth of the cell capillaries 28 cause cells to adhere to further fibres in the three dimensional network 6, such that they are adequately supported for continued growth, and in this way tissue growth may be maintained over and above conventional depth and thicknesses achieved in conventional cell cultures without the cells becoming non-viable or losing their phenotype.
  • a capillary network of cells is developed which is surrounded by a fluid perfusable support, mitigating or removing the dependency on local diffusion for nutrient supply and gaseous exchange which limit the growth of cells in known cell growth media.
  • cell orientation, position and numbers in the support means can be influenced by the presence, orientation and density/spacing of the fibres as well as the composition of the support means (e.g. its water content, nutrients, growth factors, compliance etc) .
  • Cells may also be seeded into the support means as well as or alternatively to anchoring cells to one or more fibres in the media.
  • cells may be seeded only onto and/or into the support means or both on one or more fibres and in/on the support means. Delivery of cells into the support means may be by addition of the cells in the monomer solution (in the case of a polymerised support means) prior to polymerisation/gelation, by injection into specific sites of the support means, or by loading the cells in a carrier, such as a fibre and sewing the carrier into a specific place in the support means.
  • the cells can be directed in their growth by positioning of fibres strategically within the support means and/or be driven along concentration gradients set up within the support means and/or fibres.
  • FIG. 5 illustrates a perspective view of a portion of a third preferred embodiment of cell growth scaffolding 2 of the invention.
  • the hydrogel disc 4 includes a number of different channels 30, 32, 34 running therethrough.
  • a nutrient canal 30 is inserted through the hydrogel disc 4 and connected to a nutrient reservoir (not shown) which may contain growth factors and nutrients and the like, for example.
  • the nutrient canal 30 is fluid perfusable such that nutrients flowing into the nutrient canal 30 may perfuse into the hydrogel disc 4 and throughout the fibre network 6.
  • a cell coated solid fibre 32 is also present extending through the hydrogel disc 4 and from which cell growth capillaries 36 have extended into the three dimensional fibre network 6.
  • a hollow fibre 34 in which cells are adhered to the inside surface of the hollow channel 34 has also been inserted into the hydrogel disc 4. Again cell growth capillaries 36 have extended from the hollow fibre 34 into the hydrogel disc 4 and begun to adhere onto the three dimensional fibre network 6. As can be seen in Figure 5, extended cell capillary growth 38 has begun along one or more of the fibres of the fibre network 6.
  • the nutrient canal 30 may simply be a bore machined into the hydrogel disc 4 by a suitable machine tool to create a hollow channel through the disc 4.
  • the hydrogel disc 4 may comprise many bores drilled therethrough into which cell-adhered fibres, whether porous or hollow may be inserted, or which may be used as nutrient canals or inlets/outlets for fresh nutrient solution and waste nutrient solution.
  • FIG. 6 illustrates a cell growth apparatus 53 of the invention.
  • the apparatus comprises a support body 54 into which is inserted stacked layers of cell growth scaffolding 2 of the invention, preferably stacked layers of the cell growth media 2 of the embodiment shown in Figures 1 and 2.
  • the support body 54 includes a perfusion inlet 56 which is arranged to cooperate with the perfusion channels 12 in the cell growth scaffolding 2 to form a continuous channel therethrough.
  • the support body 54 also includes a plurality of perfusion outlets 58 extending through the support body 54 and cooperable with the hydrogel discs of the cell growth scaffolding 2.
  • nutrients and other solutions may be perfused into the hydrogel discs by movement through the perfusion inlet 56 into the perfusion channels 12 and then through the hydrogel discs.
  • any waste solution may exit the hydrogel discs through the perfusion outlets 58 to be recycled and/or disposed of.
  • Figure 7 illustrates a block diagram of a second embodiment of a cell culture apparatus 53 of the invention.
  • the cell culture apparatus includes three stacked cell growth scaffolding 2 through which is extended a continuous perfusion channel 43.
  • running between the cell growth scaffolding 2 are perfusion channels 40 formed from hemispherical channels cut into the lower and upper surfaces of the hydrogel disc 4 of the cell growth media 2.
  • the cell growth scaffolding 2 are mounted in a controlled environment 42 which controls temperatures, pressures etc at optimum conditions for cell growth.
  • nutrient conduits 44 Connected to one side of the cell growth scaffolding 2 are nutrient conduits 44, and connected to the opposite side of the cell scaffolding media 2 are waste conduits 45, with both nutrient conduits 44 and waste conduits 45 being in fluid communication with the cell growth scaffolding 2.
  • the nutrient inlets 44 are connected to a oxygenation unit 46, which is in turn connected downstream of a water and nutrient replenishment unit 52.
  • the water and nutrient replenishment unit 52 is connected downstream of a pump 50.
  • a detoxification unit 48 Connected to the waste conduits 45 is a detoxification unit 48 which is connected upstream to the pump 50, thereby completing a circuit.
  • pump 50 is operated to transport water and nutrients from the replenishment unit 52 through the oxygenation unit 46 in order to oxygenate the water, and therefrom through the nutrient conduits 44 into the cell growth scaffolding 2.
  • the nutrients and water are also pumped into the nutrient channels 40 between the cell growth scaffolding 2 in order that nutrients may perfuse into all parts of the cell growth scaffolding 2.
  • fibres 6 may be any suitable synthetic or natural polymer on which cells may be grown, and particularly preferred are biopolymers such as chitosan, alginates, polysaccharides and the like for example.
  • the fluid perfusable solid support means of the invention may be other than a hydrogel, such as a viscous liquid or solid fluid perfusable support, such as a porous or absorbent solid.
  • polyacrylamide hydrogels include polyacrylate, polyacrylic acids, polyvinylpyrrolidones, or any other gel which is able to absorb a sufficient quantity of water and cell growth factor nutrient solution and through which the solution may perfuse easily to provide nutrients to growing cells.
  • use may be made in vivo or ex vivo, for example by implantation of the scaffolding into an existing tissue or organism.
  • the scaffolding may or may not include one or more cells seeded within it. If cells are seeded into the scaffolding before implantation the scaffolding may effect growth and migration of the cells into the tissue or organism to which it is implanted. If no cells are seeded, then cells from the tissue or organism may migrate into the scaffolding and grow therein.
  • the scaffolding could be used to bridge a wound or injury to tissue and encourage or begin healing through enhanced cell growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un squelette de croissance cellulaire, disposé de manière à porter, en service, une ou plusieurs cellules, qui comprend au moins une fibre. Une partie de cette fibre est disposée dans un moyen support liquide administrable par perfusion. L'invention concerne en outre des méthodes de croissance cellulaire et des procédés de production de squelettes de croissance cellulaire.
PCT/GB2004/000397 2003-01-31 2004-01-30 Ameliorations apportees dans et a propos de la croissance cellulaire WO2004067733A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0302258A GB2397824A (en) 2003-01-31 2003-01-31 Three dimensional cell culture
GB0302258.9 2003-01-31

Publications (1)

Publication Number Publication Date
WO2004067733A1 true WO2004067733A1 (fr) 2004-08-12

Family

ID=9952203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000397 WO2004067733A1 (fr) 2003-01-31 2004-01-30 Ameliorations apportees dans et a propos de la croissance cellulaire

Country Status (2)

Country Link
GB (1) GB2397824A (fr)
WO (1) WO2004067733A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102266588A (zh) * 2011-07-28 2011-12-07 西安交通大学 一种基于蔗糖纤维模板的载细胞微通道水凝胶的制备方法
WO2011150055A3 (fr) * 2010-05-25 2012-07-12 Cook Biotech Incorporated Procédés, substrats, et systèmes utiles pour l'ensemencement cellulaire de greffes médicales
AU2015202093B2 (en) * 2010-05-25 2016-11-24 Cook Biotech Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170328888A1 (en) 2016-02-25 2017-11-16 Massachusetts Institute Of Technology Neuronal Axon Mimetics For In Vitro Analysis Of Neurological Diseases, Myelination, And Drug Screening
WO2018208909A1 (fr) 2017-05-10 2018-11-15 Massachusetts Institute Of Technolgy Dispositif mimétique de cellules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2178447A (en) * 1985-06-18 1987-02-11 Yeda Res & Dev A matrix for cell cultivation in vitro
US5266476A (en) * 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5502082A (en) * 1991-12-20 1996-03-26 Alliedsignal Inc. Low density materials having good compression strength and articles formed therefrom
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510254A (en) * 1986-04-18 1996-04-23 Advanced Tissue Sciences, Inc. Three dimensional cell and tissue culture system
CA1340581C (fr) * 1986-11-20 1999-06-08 Joseph P. Vacanti Neomorphogenese chimerique d'organes par implatation cellulaire controlee, utilisant des matrices artificielles
GB0011244D0 (en) * 2000-05-11 2000-06-28 Smith & Nephew Inc Tissue regrafting
AU2002307791A1 (en) * 2001-04-30 2002-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composite scaffolds and methods using same for generating complex tissue grafts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2178447A (en) * 1985-06-18 1987-02-11 Yeda Res & Dev A matrix for cell cultivation in vitro
US5266476A (en) * 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5502082A (en) * 1991-12-20 1996-03-26 Alliedsignal Inc. Low density materials having good compression strength and articles formed therefrom

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIFFITH LINDA G: "Emerging design principles in biomaterials and scaffolds for tissue engineering.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. UNITED STATES JUN 2002, vol. 961, June 2002 (2002-06-01), pages 83 - 95, XP009032716, ISSN: 0077-8923 *
HUBBELL J A: "BIOACTIVE BIOMATERIALS", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 10, no. 2, April 1999 (1999-04-01), pages 123 - 129, XP000866483, ISSN: 0958-1669 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150055A3 (fr) * 2010-05-25 2012-07-12 Cook Biotech Incorporated Procédés, substrats, et systèmes utiles pour l'ensemencement cellulaire de greffes médicales
CN102946915A (zh) * 2010-05-25 2013-02-27 库克生物技术股份有限公司 用于医疗移植物的细胞接种的方法、基底和系统
JP2013528072A (ja) * 2010-05-25 2013-07-08 クック・バイオテック・インコーポレイテッド 医療用移植片の細胞播種に有用な方法、基質、およびシステム
AU2011258295B2 (en) * 2010-05-25 2015-01-29 Cook Biotech Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
US9115336B2 (en) 2010-05-25 2015-08-25 Muffin Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
CN102946915B (zh) * 2010-05-25 2015-12-09 库克生物技术股份有限公司 用于医疗移植物的细胞接种的方法、基底和系统
AU2015202093B2 (en) * 2010-05-25 2016-11-24 Cook Biotech Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
US10071187B2 (en) 2010-05-25 2018-09-11 Cook Biotech Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
US11077231B2 (en) 2010-05-25 2021-08-03 Muffin Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
US11173231B2 (en) 2010-05-25 2021-11-16 Muffin Incorporated Methods, substrates, and systems useful for cell seeding of medical grafts
CN102266588A (zh) * 2011-07-28 2011-12-07 西安交通大学 一种基于蔗糖纤维模板的载细胞微通道水凝胶的制备方法

Also Published As

Publication number Publication date
GB2397824A (en) 2004-08-04
GB0302258D0 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
Feng et al. Microgel assembly: Fabrication, characteristics and application in tissue engineering and regenerative medicine
Stanton et al. Bioprinting of 3D hydrogels
EP1781345B1 (fr) Immobilisation de cellules dans une matrice formee de polymeres charges biocompatibles dans des conditions d'ecoulement laminaire
KR101196365B1 (ko) Ｉｐｎ 하이드로젤 및 그 제조방법
Vunjak‐Novakovic et al. Bioreactor cultivation conditions modulate the composition and mechanical properties of tissue‐engineered cartilage
EP1781347B1 (fr) Encapsulation de cellules dans des structures de support biologiques compatibles par coacervation de polymeres charges
Kim et al. Microfluidic fabrication of multistimuli-responsive tubular hydrogels for cellular scaffolds
JP5548968B2 (ja) マイクロセルラーポリハイプポリマーの骨組の製造方法及びマイクロセルラーポリハイプポリマーの骨組
KR100871652B1 (ko) 세포 배양용 3차원 마이크로 캐리어, 이의 제조방법 및이를 이용한 세포의 3차원 부유 배양법
US20100216240A1 (en) Non-invasive automated cell proliferation apparatus
Bae et al. Fabrication of hyaluronic acid hydrogel beads for cell encapsulation
JP2003516713A6 (ja) 細胞成長媒体としてのマイクロセルラーポリマー及び新規なポリマー
CN106397819B (zh) 一种用于调控细胞三维微图案化生长的水凝胶及其制备方法
CN112322575A (zh) 一种用于培养细胞的三维凝胶支架的制备方法
Li et al. A review on thermoresponsive cell culture systems based on poly (N-isopropylacrylamide) and derivatives
Bursac et al. Mass transfer studies of tissue engineered cartilage
WO2004067733A1 (fr) Ameliorations apportees dans et a propos de la croissance cellulaire
CN100393368C (zh) 一种细胞培养和脱附用的智能膜及其制备方法
JP2005027532A (ja) 細胞培養基材及びその製造方法、並びに細胞培養方法
JP6452304B2 (ja) 細胞シート培養基材、細胞シート培養基材複合物、及び細胞シート／培養基材複合の製造方法
Semler et al. Tissue assembly guided via substrate biophysics: Applications to hepatocellular engineering
CN115369065A (zh) 一种基于水凝胶的三维细胞培养支架及其制备方法
JPH0833486A (ja) 細胞培養担体と、細胞培養方法
Zhou et al. Microspheres for cell culture
Muralidhar et al. Development of high-density cultivation systems by bioencapsulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase